Why the study?
Does intravenous nitroprusside or hydralazine increase renal digoxin clearance in patients with severe chronic congestive heart failure?
Does intravenous nitroprusside or hydralazine increase renal digoxin clearance in patients with severe chronic congestive heart failure?
Acute vasodilator therapy increases renal digoxin clearance by 50% in patients with severe heart failure, indicating a potential need for digoxin dose adjustment during long-term vasodilator therapy.
Answers are grounded in this paper and cite their sources.
May warrant caution with digoxin dosing during vasodilator therapy in severe HF; leaves open confirmation in larger studies.
We studied the effect of vasodilator therapy on renal digoxin clearance in patients with chronic congestive heart failure. Intravenous administration of nitroprusside or hydralazine to eight patients with severe heart failure produced the expected increase in cardiac output and a decrease in central circulatory pressure. Renal clearance of sodium para-aminohippurate and estimated renal blood flow increased without a change in glomerular filtration rate. Total renal clearance of digoxin increased by 50% during vasodilator therapy. Thus, acute administration of vasodilator increases renal digoxin clearance without changing glomerular filtration rate, suggesting an increase in tubular secretion of digoxin. Long-term vasodilator therapy may alter the maintenance dosage of digoxin required for optimal treatment of patients in congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Cogan et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: